Methodological requirements for clinical trials in refractory epilepsies — our experience with zonisamide

https://doi.org/10.1016/0278-5846(92)90010-CGet rights and content

Abstract

1. The guidelines for clinical evaluation of antiepileptic drugs (AEDs), proposed by the International League Against Epilepsy in 1989, were scrutinized through our clinical experiences with zonisamide.

2. Seizure type, seizure frequency, number of concomitant AEDs, and type of epilepsy were found to be essential factors in quantitatively determining the efficacy of a new drug.

3. The majority of patients selected according to the guidelines consist inevitably of those with complex partial seizures with or without secondary generalization. Consequently, the efficacy of new AEDs is evaluated mainly in patients with partial seizures, and it is difficult to evaluate their efficacy in those with refractory generalized seizures, either convulsive or nonconvulsive.

4. In order to avoid such predilection, patients with various types of generalized seizures who are taking one or two conventional AEDs should account for 30 to 40 % of the total patient population selected for clinical drug trials.

References (13)

  • COMMISSION on CLASSIFICATION and TERMINOLOGY of the INTERNATIONAL LEAGUE AGAINST EPILERSY

    Proposal for revised clinical and electroencephalographic classification of epileptic seizures

    Epilepsia

    (1981)
  • COMMISSION on ANTIEPILEPTIC DRUGS of the INTERNATIONAL LEAGUE AGAINST EPILEPSY

    Guidelines for clinical evaluation of antiepileptic drugs

    Epilepsia

    (1989)
  • K. Fukushima et al.

    Phase II study of zonisamide (ZNA), a new antiepileptic drug, in epileptic children

    Jpn J Pediatr

    (1987)
  • T. Ito et al.

    Pharmacokinetic studies of AD-810, a new antiepileptic compound — phase I trials

    Arzneimittileforschung

    (1982)
  • K. Matsumoto et al.

    Absorption, distribution and excretion of 3-(sulfamoyl 14C methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men

    Arzneimittelforschung

    (1983)
  • H. Oguhi et al.

    Phase III study of a new antiepileptic AD-810, zonisamide in childhood epilepsy

    Jpn J Pediatr

    (1988)
There are more references available in the full text version of this article.

Cited by (73)

  • Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis.

    2021, Seizure
    Citation Excerpt :

    Lethargy (8/15), irritability (5/15), gastroenteritis (2/15), dryness of skin and mouth (1/15), loss of appetite (1/15), and metabolic acidosis (1/15) were predominant adverse effects of zonisamide. Yagi et al [19]. have explored the efficacy of zonisamide in nine patients with epileptic spasms, out of which 2 patients had >50% reduction in spasms, but further details of these patients have not been described in the study.

  • Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy

    2019, Epilepsy Research
    Citation Excerpt :

    Benzodiazepine derivatives are broad-spectrum AEDs being used in both FS and GS, however, they are considered second-line drugs being useful in adjunctive therapy, which may be related to their sedating side effects and potential tachyphylaxis (Callaghan and Goggin, 1988; Specht et al., 1989; Canadian Clobazam Cooperative Group, 1991). Since introduction of CBZ and VPA in late 1960′s, which were major drugs during the era of conventional drug, there was a long hibernation period in the new drug development for epilepsy until the marketing approval of vigabatrin (VGB) in UK and zonisamide (ZNS) in Japan in 1989 (Sander et al., 1990; Yagi and Seino, 1992), which opened the “Era of New AEDs” (Allen, 1995). Seventeen new drugs have been introduced to the market until now and we have at least 25 AEDs, including both conventional and new AEDs, to use in our practice, which is completely a different environment for pharmacotherapy of epilepsy from the era of conventional AEDs (Santulli et al., 2016; Shih et al., 2017).

  • Zonisamide for refractory juvenile absence epilepsy

    2014, Epilepsy Research
    Citation Excerpt :

    Different studies have shown a positive effect in the treatment of AS but these studies included heterogeneous group of patients with different types of generalized epilepsies and with a clear predominance of children (Zaccara and Specchio, 2009). The efficacy of ZNS on AS has been shown for the first time in a small series of patients in a prospective study (Yagi and Seino, 1992). Later, Yamauchi and Aikawa (2004) in their post-marketing surveillance study reported that the responder rate (proportion of patients with at least 50% seizure reduction) was 87.5% (n = 8) for typical absences and 46.3% (n = 54) for atypical absences.

View all citing articles on Scopus
View full text